HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DXM Panel Proposes Augmenting, Improving Education To Curb Abuse

This article was originally published in The Tan Sheet

Executive Summary

Members of an FDA panel tipped their hats to the Consumer Healthcare Product Association's efforts to reduce dextromethorphan abuse, but floated enhancements to the program

You may also be interested in...



Another State Age-Restricts Sales Of DXM OTC Drugs As Teens' Abuse Of Ingredient Grows

Percentage of 10th- and 12th-graders in MTF survey using DXM-containing OTCs for inebriation effects had declined while rate of 8th-graders increased from 2018 to 2019. However, abuse of OTC drugs containing the cough suppressant increased in all age groups in 2020 survey.

OTC Pseudoephedrine Purchases In Arkansas Require In-State Identification

An Arkansas law limits sales of pseudoephedrine-containing OTC products to consumers with in-state identification, pioneering a tactic in states' attempts to curb illegal purchases.

CHPA Splits Roles Of Government Affairs VP, General Counsel And Secretary

Long-time drug industry lobbyist Bill Head will take over as VP of government affairs at the Consumer Healthcare Products Association following Andrew Fish's recent departure.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134904

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel